SLC5A2 and hydrops fetalis: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated a class effect in reducing HF hospitalizations in patients with or without baseline cardiovascular disease but also in preserving renal function [29,30].